Latest News

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Study Highlights Importance of Achieving CR After Intensive Therapy for AML

Patients with acute myeloid leukemia (AML) who achieve complete remission have improved overall survival.

No Induction Therapy Superior to Another for Higher-risk AML, MDS

No Induction Therapy Superior to Another for Higher-risk AML, MDS

In higher-risk patients who fail hypomethylating agent treatment, no induction strategy is superior to another with respect to outcomes and safety.

Condensed HDAC Schedule Superior to Standard Schedule in AML

Condensed HDAC Schedule Superior to Standard Schedule in AML

Consolidation therapy with a condensed schedule of high-dose cytarabine (HDAC) is superior to a standard schedule.

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

Higher Idarubicin Dose During Consolidation Improves Leukemia-free Survival in AML

A higher dose of idarubicin during consolidation therapy improves leukemia-free survival without increasing non-hematologic toxicity.

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Brentuximab Vedotin Superior to Standard of Care Options in CTCL

Treatment with brentuximab vedotin is associated with superior clinical outcomes compared with standard of care options.

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemo-free Induction Efficacious in Younger Patients With Mantle Cell Lymphoma

Chemotherapy-free induction with ibrutinib and rituximab is efficacious and well-tolerated among young patients.

VcR-CVAD Regimen Induces Durable Remissions in Mantle Cell Lymphoma

VcR-CVAD Regimen Induces Durable Remissions in Mantle Cell Lymphoma

Incorporation of bortezomib into VcR-CVAD followed by rituximab maintenance demonstrated high rates of durable remissions.

Venetoclax + LDAC Appears Active, Safe in Older Patients With AML

Venetoclax + LDAC Appears Active, Safe in Older Patients With AML

Venetoclax in combination with low-dose cytarabine appears active in older, treatment-naive patients with acute myeloid leukemia.

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab Maintenance Prolongs Survival Among Younger Patients With Mantle Cell Lymphoma

Rituximab maintenance following autologous hematopoietic cell transplantation prolongs survival among younger patients with mantle cell lymphoma.

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab Vedotin + RCHP Active in High-intermediate/High Risk DLBCL

Brentuximab vedotin in combination with RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) is active as a frontline therapy.

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Study Identifies Ultra-high Risk Category of Patients With DLBCL

Ultra-high risk category of patients with diffuse large B-cell lymphoma (DLBCL) who have dismal outcomes on existing therapies.

Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation

Nivolumab + Ibrutinib Active in Relapsed/Refractory CLL and Richter Transformation

The combination of nivolumab and ibrutinib is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Clonal Hematopoiesis Increases Risk of Therapy-related Myeloid Malignancies

Clonal Hematopoiesis Increases Risk of Therapy-related Myeloid Malignancies

Clonal hematopoiesis at the time of primary cancer diagnosis was associated with a significantly increased risk of therapy-related myeloid neoplasm development.

Biosimilar to Trastuzumab Has Equivalent Activity in Breast Cancer

Biosimilar to Trastuzumab Has Equivalent Activity in Breast Cancer

Proposed trastuzumab biosimilar MYL-1401O demonstrated equivalent activity compared with trastuzumab among women with metastatic breast cancer.

Ofatumumab Monotherapy Active in Waldenström Macroglobulinemia

Ofatumumab Monotherapy Active in Waldenström Macroglobulinemia

Ofatumumab monotherapy was active and well tolerated among patients with previously untreated or relapsed Waldenström macroglobulinemia.

PF-05280014 Shows Equivalent ORR to Trastuzumab in HER2-positive Breast Cancer

PF-05280014 Shows Equivalent ORR to Trastuzumab in HER2-positive Breast Cancer

Pfizer's REFLECTIONS B3271002 study evaluating PF-05280014 as a potential biomarker to trastuzumab (Herceptin) met its primary endpoint.

FDA Grants Priority Review for Pembrolizumab in Treatment of Hodgkin Lymphoma

FDA Grants Priority Review for Pembrolizumab in Treatment of Hodgkin Lymphoma

The FDA has granted Priority Review to a sBLA that is seeking approval for pembrolizumab (Keytruda) for the treatment of Hodgkin lymphoma.

Rucaparib Prolongs PFS in Ovarian Cancer

Rucaparib Prolongs PFS in Ovarian Cancer

Rucaparib significantly prolongs progression-free survival among patients with BRCA-mutant or BRCA wild-type ovarian carcinomas.

Fulvestrant Superior to Anastrozole for HR-positive Advanced Breast Cancer

Fulvestrant Superior to Anastrozole for HR-positive Advanced Breast Cancer

Among patients with previously untreated breast cancer, endocrine therapy with fulvestrant significantly prolonged progression-free survival.

Smoking Cessation at any Age May Reduce Mortality Risk

Smoking Cessation at any Age May Reduce Mortality Risk

Smoking cessation improves all-cause mortality, regardless of the age at which one quits.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters